Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469367 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25597040 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25599185 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21699485 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18179643 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25668291 | 0.86 | XIAP (0.36) | — | |
| SCHEMBL22192668 | 0.84 | DPP4 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19201191 | 0.83 | FFAR2 (0.32) | — | |
| SCHEMBL23105983 | 0.83 | — | — | |
| SCHEMBL19201193 | 0.83 | FFAR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265275-A1 | TROP2 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265274-A1 | B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4257153-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023173074-A2 | IMMUNOSTIMULANT-CYTOTOXIC CONJUGATE COMPOSITION AND METHODS FOR CANCER TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023098831-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | 嘉兴优博生物技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023006084-A1 | ANTI-DLL3 ANTIBODY AND PREPARATION METHOD THEREFOR, DRUG CONJUGATE AND APPLICATION THEREOF | 上海复旦张江生物医药股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2020065408-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2020-04-02 | — | — | WO | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-09-05 | — | — | US | disclosed |
| EP-3498301-A1 | KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-3134124-B1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017153432-A1 | A NEW UNIVERSAL METHOD TO CAPTURE AND ANALYZE ADCS FOR CHARACTERIZATION OF DRUG DISTRIBUTION AND THE DRUG-TO-ANTIBODY RATIO IN BIOLOGICAL SAMPLES | PIERRE FABRE MEDICAMENT (FR) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016173682-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015162291-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ALDH1A1 982/4885SMN1; SMN2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.